Amlodipine Use in ESRD Patients

Safety Profile in Renal Failure

ACE inhibitors are explicitly not contraindicated in end-stage renal disease and are used frequently in dialysis patients, and the same principle applies to calcium channel blockers like amlodipine, according to the American Heart Association 1

No difference in cardiovascular outcomes was found between chlorthalidone, amlodipine, and lisinopril in patients with eGFR <60 mL/min/1.73 m², as reported by the National Kidney Foundation 2
Amlodipine showed better preservation of renal function (less marked decline in creatinine slope and better preserved creatinine clearance) compared to chlorthalidone and lisinopril arms, based on guidelines from the American Society of Nephrology 3
Studies in hemodialysis patients showed benefit from amlodipine over placebo in preventing cardiovascular events, according to the American Journal of Kidney Diseases 2

Do not administer amlodipine to patients treated with polyacrylonitrile dialysis membranes due to risk of anaphylactoid dialyzer reactions with ACE inhibitors; while this warning is specific to ACE inhibitors, caution is warranted, as recommended by the American Heart Association 1
Unlike some ACE inhibitors, amlodipine's lack of significant renal excretion means therapy remains stable regardless of dialysis schedule, according to the American College of Cardiology 1

Amlodipine is appropriate as monotherapy or combination therapy for hypertension management in established ESRD, as stated by the European Renal Association 4

Watch for peripheral edema, the most common side effect; consider dose reduction if it develops, as advised by the American College of Physicians 5
Monitor for orthostatic hypotension, particularly when initiating therapy in dialysis patients, as recommended by the National Institute of Diabetes and Digestive and Kidney Diseases 5